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Abstract Gray horses spontaneously develop metastatic
melanomas that resemble human disease, and this is often
accompanied with metastasis to other organs. Unlike in
other species, the establishment of primary equine melano-
ma cultures that could be used to develop new therapeutic
approaches has remained a major challenge. The purpose of
the study was to develop a protocol for routine isolation and
cultivation of primary equine melanocytes. Melanoma
tissues were excised from 13 horses under local anesthesia,
mainly from the perianal area. The melanoma cells were
isolated from the melanoma tissue by serial enzymatic
digestion using dispase and collagenase. Out of the 13
excised melanomas, cell cultures from eight melanomas
were established, which corresponded to a success rate
62%. These cells showed different degrees of melanin
pigmentation. Characterization of these cells using confocal
microscopy, FACs analysis and western blotting showed
that they expressed melanoma-associated antigens; Melan-
A, MAGE-1, and MAGE-3, and PCNA expression was
higher in fast-proliferating isolates. The protocol we
developed and established proved successful for routine
isolation and cultivation of primary equine melanoma cells.
This method provided a large number of primary equine
melanoma cells that could be used to study new therapeutic
approaches for treatment of equine melanomas.
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Introduction
Gray horses frequently develop cutaneous melanomas
which eventually metastasize, especially during the second
half of their life. It is estimated that up to 80% of gray
horses older that 15 y develop melanoma (McFadyean
1933; Rodríguez et al. 1997). Equine melanomas are
classified according to their clinical patterns as melanocytic
nevi (melanocytoma), dermal melanoma, dermal melano-
matosis (multiple, often confluent dermal melanomas) or
anaplastic malignant melanoma. Melanocytic nevi are
encountered in younger horses of all colors, and are
discrete, located in the superficial dermis or dermo-
epidermal junction and are benign. Dermal melanomas are
located in the deep dermis. Anaplastic malignant melanomas
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are in contrast to melanocytic nevi and dermal melanomas
highly polymorphic, often poorly pigmented and exhibit a
high mitotic rate. Equine dermal melanoma in gray horses
mainly develop under the tail root, in the anal, perianal and
genital regions, perineum, lips and eyelids as nodules with a
low tendency to metastasis in contrast to equine dermal
melanomatosis which have high incidence of metastasis.
Both types of melanoma are hard to distinguish from each
other and, to date, their metastatic potential cannot be
determined by histological analysis (Valentine 1995;
Seltenhammer et al. 2004).
Diagnosis of equine melanoma is based on clinical and
histopathological examination including cytology. Often,
melanomas are not treated because of their initial benign
behavior, slow-growth, proximity to major vessels and vital
structures, or extensive local invasion (MacGillivray et al.
2002). There also may be increased risk of metastasis after
mechanical stimulation of a melanoma. Treatments include
surgical excision, partial tail amputation, cryotherapy, oral
systemic therapy with cimetidine, and intralesional chemo-
therapy with cisplatin (Frederick 1990; Goetz et al. 1990;
Goetz and Long 1993; Théon et al. 1993; Warnick et al.
1995; Freeman 1999; Rowe and Sullins 2004). Except for
small and well-demarcated melanomas, surgical excision
has poor prognosis (Cox et al. 1989).
Recently, research on treatment of human and animal
melanomas has focused on immunoprophylaxis. A crude
whole-cell melanoma vaccine has been used with non-
conclusive results in the management of equine neoplasia
(Jeglum 1999; MacGillivray et al. 2002). Intratumoral
injection of interleukin-18 and interleukin-12 DNAs showed
some inhibitory effect on melanoma growth in gray horses
(Heinzerling et al. 2001; Stähli 2005). However, a vaccine
resulting in complete remission is still to be developed.
New therapeutic approaches for treatment of equine
melanoma are therefore required. For this to be achieved,
preclinical models need to be established to allow the
determination of the efficacy of new therapeutic
approaches. This include the use of in vitro cultured
melanoma cells, which would offer various advantages,
such as being derived in large quantities and being easily
accessible for drugs and vaccine testing. Unlike in other
species, the establishment of primary equine melanoma
cultures has remained a major challenge. Additionally, a
reliable marker system for equine melanomas still remains
to be established (Seltenhammer et al. 2004).
The objective of this study was to establish a method for
routine isolation and cultivation of primary equine melano-
ma cell cultures. To ensure that the cultures isolated were
melanoma cells, the presence of some of the known
melanoma-associated antigens (MAA) was determined.
These included; Melan-A, MAGE-1, and MAGE-3.
Melan-A is a melanocyte differentiation antigen, recog-
nized by autologous cytotoxic T lymphocytes. Melan-A is
also known as MART-1 (melanoma antigen recognized by
T cells 1). Currently, little is known about the function of
Melan-A in melanocyte development and differentiation
(Koenig et al. 2001; Murer et al. 2004; van Dinten et al.
2005). Melan-A/MART is expressed in normal immature
melanocytes and in the majority (more that 90%) of fresh
melanoma tumors and melanoma cell lines, but it is not
expressed in other cells and other tumors. Because of the
high percentage of melanoma tumors showing Melan-A
expression and due to its immunogenicity, this antigen is
one of the targets for cellular immunotherapy against
malignant melanoma. Its expression can be used as a
predictive factor for the selection of patients eligible for
Melan-A-based immunotherapy (van Dinten et al. 2005).
The second group of antigens includes melanoma
antigen-encoding (MAGE) family members which are
normally expressed in adult testis. MAGE family of
proteins are also expressed in various tumor types but
silenced in normal adult tissue. MAGE-1 and MAGE-3
have been detected in melanoma cells and their ectopic
expression is characteristic of malignant transformations
(Urosevic et al. 2005). These antigens are presented in
HLA-class-1-restricted fashion and can be recognized by
antigen specific cytolytic T lymphocytes (CTL), which can
eliminate melanoma cells upon recognition of these anti-
gens (Boon and van der Bruggen 1996). The efficiency of
this antigen presentation may depend on both melanoma-
and host-immune specific factors. Melanoma-specific fac-
tors encompass the levels of MAA expression as well as the
level of HLA class1 molecule expression (Urosevic et al.
2005). In addition to the above markers, the expression of
proliferating cell nuclear antigen (PCNA) was deter-
mined. PCNA had previously been correlated with
aggressive behavior in human cutaneous malignant
melanomas (Ben-Izhak et al. 2002).
In this study, we established the isolation and cultivation
of primary equine melanoma cells from excised melanoma
tissue. We investigate the expression of several MAA—
Melan-A, MAGE-1, MAGE-3, and PCNA, by means of
Western blotting, FACS analysis, and confocal microscopy.
Materials and Methods
Excision of melanoma tissue. Melanomas were excised
from 13 healthy gray horses (Table 1). The horses were
placed in stalls and sedated intravenously with 0.01 mg/kg
detomidine (Domosedan®—Pfizer AG, Zurich, Switzer-
land) and 0.02 mg/kg butorphanol (Morphasol®, Dr. E.
Graeub AG, Bern, Switzerland). This was followed by a
continuous rate infusion of detomidine and the flow was
adjusted when needed. Just before surgery, 1 mg/kg flunixin
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meglumine (Fluniximin®, Berna AG, Bern, Switzerland)
was administered intravenously. Tumors that were selected
had an average diameter size of 4 to 20 mm, were easily
accessible and the excision site chosen had low risk of
wound-healing complications. The hair was clipped and the
surgical site prepared aseptically. Lidocaine 2% (G. Streuli &
Co. AG, Uznach, Switzerland) was used as the local
anesthesia and it was administered subcutaneously on the
perimeter of the tumor. The melanoma was excised accord-
ing to standard surgical methods. The volume of the excised
tumor material was estimated. Immediately after excision,
the tumor tissue was divided in two pieces and one piece was
placed in 4% PBS-buffered formalin (pH 7) for histological
examination, while the other piece was placed in sterile
Dulbecco's phosphate-buffered saline (PBS, Invitrogen,
Carlsbad, CA) containing 1% Penicillin–streptomycin
(Pen–Strep, Invitrogen) at room temperature, for isolation
of melanoma cell cultures. It was immediately transferred to
the cell culture laboratory. Time from excision to further
processing of the cells was 15 to 20 min for all excised
tumors.
Histological examination. Fixed tissue was embedded in
paraffin and 4-μm sections were cut and stained with
hematoxylin and eosin. Histological sections were evaluat-
ed for the following features: location of the tumor (e.g.,
superficial or deep dermis), presence of junctional activity,
type of neoplastic cells (e.g., round, epitheloid, spindle-
shaped), degree of pigmentation, degree of polymorphism,
mitotic activity, presence of inflammation or necrosis
within the tumor, growth pattern (e.g., expansive or
infiltrative), lesions in the adjacent tissue (e.g., ulceration
of the epidermis, dermatitis). No classification into benign
and malignant melanomas was made as there are no reliable
criteria to differentiate them on a histological basis.
However, it should be noted that about two-thirds of the
equine melanomas are thought to undergo progression
and be capable of metastasis (Scott and Miller 2003;
Seltenhammer et al. 2004).
Isolation of primary equine melanoma cells. The excised
melanoma tissue was washed with PBS containing 1%
Pen–Strep to get rid of blood. All the connective tissue
surrounding the melanoma tissue was excised. The mela-
noma tissue was minced with scalpel blade into 1–2-mm
pieces and washed again with PBS. Samples were
subsequently digested with dispase (Boehringer Mannheim,
Mannheim, Germany) diluted 1:2 in RPMI 1640 (Gibco,
Carlsbad, CA), for 3 h at 37°C. After centrifugation at
1,500 rpm for 5 min, the supernatant was discarded and
collagenase (Sigma, St. Louis, MO) diluted 1:100 in Tris-
buffered saline (TBS) containing 10 mM CaCl2, was added
and mixture incubated for 2 h at 37°C. The reaction was
stopped by the addition of 1/10 vol. of TNE buffer (0.05 M
Tris base, 0.15MNaCl, 0.01M EDTA, pH 7.4) for 5–10 min.
The cells were subsequently washed twice with RPMI 1640
medium containing 10% FCS and 1% Pen–Strep. Detached
cells were separated from undigested melanoma tissue by
filtration through sterile 70-μm nylon cell strainers
(Falcon, Bedford, MA), and filtered cells were subse-
quently cultivated at 37°C and 5% CO2 in RPMI 1640
supplemented with 10% heat-inactivated fetal calf serum
(FCS; Invitrogen), 5 mM glutamine (Invitrogen), 1 mM
sodium pyruvate (Gibco) and 1% of an antibiotic mixture
containing 10,000 U/ml penicillin and 10,000 μg/ml
streptomycin (Gibco).
All cultures were examined daily for growth, adherence,
and presence of contamination using an inverted light
microscope. Media was replaced once per week and the
first passage done once the cells reached >90% confluence.
Table 1. Characteristics of excised melanoma tissue and presence or absence of growth after isolation
Melanoma Age (y) Sex Breed Site Result
M1 16 mc Irish WB Head G
M2 17 mc Swiss WB Pectoral NG
M4 20 mc Anglo-Arabian Perianal G
M8 10 mc Lusitano Perianal G
M9 14 f Arabian Perianal G
M10 12 mc Swiss WB Perianal NG
M11 9 mc Durch WB Head NG
M12 12 mc Swiss WB Perianal G/NGa
M13 26 mc Andalusian Perianal NG
M14 12 mc Andalusian Perianal G
M15 8 f Swiss WB Dorsal tail NG
M16 6 m Andalusian Perianal G
M17 9 f Arabian Ventral tail G
m Male intact, mc male castrated, f female, ND histological examination not done, WB warmblood, G cell growth, NG no cell growth
a Initial growth followed by cell necrosis after first cell division
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A 1:2 dilution was used for slow-proliferating cells and 1:3
dilution for fast-proliferating cells. Cells that grew after
isolation until the first passage were passage 0 (P0) cells,
and after the first passage they were P1, and this applied for
the subsequent passages. For our experiments we used
melanoma isolates in passages P0–P3.
To ensure that the melanocytes were not contaminated
with fibroblasts, one plate of the P1 cells from the fast-
proliferating M9 and M14 isolated were treated with
100 μg/ml geneticin (G418), which is known to completely
inhibit fibroblast growth in melanocyte isolates (Halaban
and Alfano 1984).
For the cell passage, confluent adhering cells were
detached with a solution containing 0.05% trypsin and
0.02% ethylene diamine tetra-acetic acid (EDTA; Invitro-
gen), inactivated with fresh media containing 10% FCS.
Some of the detached cells were used to make stabilate
stocks for storage in liquid nitrogen. After inactivation of
trypsin, these cells were resuspended in Recovery™ cell
culture freezing medium (Invitrogen) and cells were placed
in Nalgene™ Cryo 1° Freezing container, which had
isopropanol insulation. They were stored at −80°C over-
night and then transferred to liquid nitrogen.
An established equine melanoma cell line (kindly
provided by Dr. M. Seltenhammer, University of Veterinary
Medicine, Vienna, Austria) was used as a positive control
and was grown under the same conditions as the isolated
primary melanoma cells. This positive control cell line had
been in culture and had undergone several passages; the
cells we used were after passage 30.
Primary equine muscle fibroblasts (passage 2) were used
as negative control cells. Muscle tissue (≈0.5 cm) was
excised from the lower abdomen of a live horse and
primary fibroblasts were isolated using sequential digestion
with dispase and collagenase similar to the melanoma cells,
as stated above. The isolated cells were then propagated in
RPMI 1640 supplemented with 10% heat-inactivated fetal
calf serum (FCS; Invitrogen) and 1% of an antibiotic mixture
containing 10,000 U/ml penicillin and 10,000 μg/ml
streptomycin (Gibco).
Antibodies. The mouse monoclonal Melan-A antibody with
specific reactivity for human and horse melanomas was
purchased from Biomeda AG, Zurich, Switzerland, while
the mouse polyclonal MAGE-1 and MAGE-3 antibodies
were a gift from Prof. Giulio C. Spagnoli, University of
Basel. Mouse Monoclonal anti-PCNA and anti-tubulin
antibody were purchased from Santa Cruz Biotechnology,
Santa Cruz, CA. The tubulin antibody was used as a
loading control.
FACS analysis for melanoma cells. For FACS analysis, the
procedures described by Urosevic et al. (2005) were used
with some modifications. In brief, passage 2 cells were
harvested by treatment with trypsin, washed once with
medium containing 10% FCS. The cells were subsequently
washed once with F-PBS (phosphate-buffered saline with-
out Ca2+/Mg2+ containing 1% FCS and 0.02% sodium
azide). Cells were then fixed with 4% paraformaldehyde for
20 min, at room temperature. This was followed by
permeabilization with PBS containing 0.2% Triton X-100
for 10 min at room temperature. The cells were then
washed twice with F-PBS and incubated with primary
antibody against respective MAA, at room temperature for
1 h on a roller (200 μl PBS containing 2% BSA, 0.1%
Triton X-100). The following antibody dilutions were used;
Melan-A (1:100), 77B (MAGE-1; 1:25) and 57B (MAGE-
3; 1:25). The cells were then washed twice with F-PBS and
incubate with secondary anti-mouse FITC conjugated
antibody (1:250) in 200 μl PBS containing 2% BSA,
0.1% Triton X-100 on ice in the dark for 1 h. Anti-mouse
antibody not conjugated to a fluorescent dye was used as
negative control. Cells were washed twice with F-PBS and
incubated in 0.5% paraformaldehyde for 5 min. For FACS
analysis, at least 10,000 cells were acquired and fluores-
cence detected using Beckman Coulter FC500 cytometer
and analyzed using a CXP analysis software.
Immunofluorescent labeling. The melanoma cells after one
passage were seeded onto four-chamber slides (Lab-Tek®,
Nalge Nunc International, Rochester, NY) and allowed to
grow until they reached an 80% confluence which was
achieved within 3 d after seeding. The medium was
aspirated, cells washed twice with PBS before fixation
with 4% paraformadehyde for 20 min at room temperature.
Cells were then permeabilized in PBS containing 0.2%
Triton X-100 for 10 min. Cells were washed twice in PBS
and subsequently blocked in PBS containing 2% BSA and
0.1% Triton X-100 for 45 min at room temperature.
The cells were subsequently incubated with primary
antibodies; Melan-A (1:100), MAGE-1 (1:25), and MAGE-
3 (1:25) dissolved in PBS containing 2% BSA and 0.1%
Triton X-100, for 1 h at room temperature. Cells were then
subsequently washed twice with PBS.
Secondary FITC-labeled anti-mouse antibody (1:250)
dissolved in PBS containing 2% BSA and 0.1% Triton X-
100 was then added and the slides completely covered with
aluminum foil and incubated for 90 min at room temper-
ature. From this point onwards, all subsequent steps were
done in the dark to avoid bleaching of the fluorescent
probes. The cells were then washed once in PBS before
300 μl of DAPI (0.1 μg/ml) was added and incubation done
for 5–10 min. The cells were washed twice with PBS.
The chambers were torn away and the rubber at the
chamber boundaries removed carefully to avoid damaging
of the cell monolayer. One to two drops of mounting
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solution (Vector Shield) was added on to cells of eachwell, and
cells were subsequently covered with cover slips and sealed
with transparent nail polish. Slides were protected from light
and stored at 4°C until examined by confocal microscopy.
SDS-PAGE and immunoblotting. Melanoma cell cultures
were washed twice with PBS containing protease inhibitors.
The cells were then scrapped off in cold PBS containing
protease inhibitors. After centrifugation, the cell pellet was lysed
and samples were analyzed immediately or stored at −80°C.
The protein concentrations were determined with the
Bio-Rad DC protein assay before analysis by SDS-PAGE
and immunoblotting. Samples were denatured by heating
for 5 min at 95°C, before being loaded onto a 10% (w/v) gel
for MAGE-1, MAGE-3, PCNA, and tubulin detection
(20 μg protein per slot) and onto a 20% (w/v) gel for
Melan-A detection (20 μg protein per slot). After separation
by electrophoresis, the proteins were transferred electro-
phoretically onto hybond-C nitrocellulose membranes,
which were blocked for 1 h at room temperature in Tris-
buffered saline (TBS; 500 mM NaCl, 9 mM Tris–HCl,
pH 7.4) and 0.1% Tween 20 (TBST), containing 5% (w/v)
skimmed milk powder. The antibody labeling was done in
TBST containing 1% (w/v) skimmed milk powder for 2 h at
room temperature for polyclonal mouse anti-MAGE-1
(1:50), MAGE-3 (1:50), PCNA (1:1,000), and tubulin
(1:1,000), while for Melan-A, the labeling was done for
12 h at 4°C with the monoclonal mouse anti-equine Melan-
A antibody (1:200). The nitrocellulose membranes were
washed three times in TBST containing 1% (w/v) skimmed
milk powder for 45 min at 4°C, and incubated with the anti-
mouse (1:3,000) secondary antibody conjugated with
alkaline phosphatase in the same buffer for 2 h at room
temperature. They were analyzed with an enhanced
chemiluminescence immunoblotting detection system.
Results
Macroscopic and histological findings. Six of the eight
primary melanoma cell cultures that grew in vitro were
from tumors that were excised mainly from the perianal
region, while the other two were from the head, and the
ventral base of the tail (Table 1). These tumors were located
intradermally. The melanoma tissue consisted of a black
pigmented solid mass that was easy to differentiate from
normal tissue. The consistency of the tumor mass differed,
some being very firm and resistant to dissection while the
others were soft and easy to dissect. In some melanomas,
the center was composed of dark pigmented material that
was gritty and it disintegrated easily when touched. The
shapes of the tumors were round, oval, or irregular.
Figure 1. Hematoxylin and eo-
sin staining of melanoma tissues
excised from dermally located
melanoma M4 (a) and M9 (b).
M4 (a) was pigmented, non-
encapsulated and had infiltrative
growth. It was composed of
medium to large sized, round,
polyhedral (arrow) or plump-
spindled (arrowhead) cells that
contained large amounts of
melanin pigment. M9 (b) was
moderately pigmented, well cir-
cumscribed, with mild infiltra-
tive growth. It was densely
packed with spindle-shaped
cells with ovoid nucleoli with
low to moderate amounts of
melanin pigment.
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All melanocytic tumors were dermally located, non-
encapsulated, infiltratively growing, and usually composed
of a mixed population of spindle, round, and polygonal
neoplastic cells (Fig. 1a and b) with a variable number of
admixed melanophages. No anaplastic melanoma was
observed. The degree of pigmentation was variable, but
usually high and no amelanotic tumor was seen. The
nuclear shape varied and was either ovoid or round, the
chromatin was mostly finely stripped and one, or in rare
cases, two small but distinct nucleoli were present. The
degree of anisokaryosis and ansiocytosis was mild to
moderate and mitotic figures were not observed. Some
tumors were in close proximity to the epidermis; however,
junctional activity was not present. Small perivascular nests
of tumor cells were present in M4, and M12 and, in two
cases (M4 and M14), a tumor embolus within a vessel was
detected. In five cases (M4, M8, M13, M15, M16), small,
only histologically detectable periadnexal neoplastic pro-
liferations were present in addition to the main tumor mass.
A predominantly lymphocytic inflammatory reaction, most-
ly confined to the border of the tumor, was present in one
case (M15) and a necrotic center with dystrophic mineral-
ization in another (M2). From 13 excised melanomas, five
did not grow in culture. However, histologically, no
difference was detected between these five and the isolates
that successfully grew in culture.
Melanoma cell cultures. Out of the 13 excised melanoma
tissues, we succeeded in establishing eight melanoma
primary cell cultures, which corresponded to a success rate
of 62%. It took a minimum of 7 d for adherent cell colonies
to be detected on the culture dishes and 14–21 d to begin to
proliferate. The shape of the isolated melanoma cells
differed ranging from bipolar and slim cells, tripolar cells,
Figure 2. Phase contrast microscopy of cells isolated from melanoma tissues of the following melanoma; M8 (a)—P0, M17 (b)—P1, M12 (c)—
P0, M14 (d, h, i)—P1, M1 (e)—P1, M9 (f)—P1 and positive control (g)—P30. The passage numbers are represented in italics.
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cells with polydendrites to rounded cells (Fig. 2a,b, and c).
Some of the cultures grew as a uniform monolayer (Fig. 2d)
while others accumulated as clusters of cells with pigmen-
tation at the center (Fig. 2e).
Most cultures proliferated slowly and required about 7 d
to reach confluence after a 1:2 dilution. In contrast, two
cultures, M9 and M14, required 3 d to reach confluence after
a dilution of 1:3. M9 had two distinct cell populations, one
being a very fast-proliferating rounded cell population with
some cells having long dendrites extending to the next
rounded colony. These populations were surrounded by
slow-proliferating bipolar and tripolar spindle-shaped cells
(Fig. 2f). Pigmentation in these cells was low. The shape of
the rounded cells was similar to our positive control cells
that were highly proliferating and had similar dendritic
extensions to the next rounded colony (Fig. 2g). There was
no difference in cell properties or proliferation of the M9
and M14 cells that were treated with 100 μg/ml genetic
(G418), which indicated that our cells were not contami-
nated with fibroblasts.
Pigmentation in the different cultures showed variations,
ranging from low, intermediate to heavily pigmented cells. In
some bipolar and tripolar cells, pigmentation was found at
the center of the cell in the perinuclear area (Fig. 2a) or in the
middle of the cluster of several cells (Fig. 2e). In one culture
(M12), very few melanocytes attached to the plate surface.
These cells were larger than in the other cultures and they
had pigmentation in the perinuclear regions (Fig 2c). These
cells died off after the first division. In M14 culture, a lot of
cells in several large sections of the monolayer had heavy
pigmentation and there were also several huge irregular
cells filled up with heavily pigmented granules (Fig. 2h and i).
After a few days, the heavily pigmented cells became
necrotic and detached from the plate surface.
After the first passage, cells required less time to reach
confluence, on average, one to two weeks. The proportion of
cells having clear pigmentation by the time confluence was
reached decreased although pigmentation increased upon
longer cultivation, e.g., after 2 wk. The cells were maintained
in culture for a maximum of three passages. After this, cell
stabilates were prepared and stored in liquid nitrogen.
FACS analysis. FACS analysis proved to be sensitive in
detection of expression of melanoma-associated antigens.
More than 80% of the positive control cells expressed
Melan-A, while in the cultivated isolates, the proportion of
cells expressing Melan-A between 20% and 42%. Less than
10% of the cells in all the isolates including the positive
control expressed either MAGE-1 or MAGE-3 (Fig. 3). The
MAGE-1 and MAGE-3 signal were also low.
Confocal microscopy. To confirm the intracellular localiza-
tion of the MAA, confocal microscopy was done. Fluores-
cent signals of several sections at different height of the
sample were examined and results of the different z-
sections shown. Our FACS analysis results were confirmed
with confocal microscopy. All the positive control cells in
the acquired microscopic field had very high cytoplasmic
expression of Melan-A (Fig. 4a and b; arrows). In our
isolates, there was expression of Melan-A, although only a
few cells had distinctively high amounts of Melan-A
(arrows). A proportion of the remaining cells showed
Melan-A expression; however, the amount of protein was
lower (Fig. 4c–f).
In all the cell cultures, including the positive control cells,
very few of the cells expressed MAGE-1 and MAGE-3
(arrows), and the amount of protein detected by confocal
microscopy was low (Fig. 5a–d).
Western blotting. Western blotting was not as sensitive as
the FACS and confocal microscopy in detecting the
presence of MAAs. Several unspecific bands were detected
using MAGE-1 and MAGE-3 polyclonal antibodies al-
though none of these bands specifically corresponded with
the molecular weights of MAGE-1 (46 kDA) or MAGE-3
(49 kDA). Using the Melan-A monoclonal antibody, high
amounts of Melan-A (18–22 kDA) could only be detected
in the positive control cell culture (Fig. 6). There was no
signal from the other isolates using the normal ECL
detection. When the more sensitive DURA was used,
several unspecific bands appeared (data not shown). PCNA
signal was detected in all the isolates, the signal was
stronger in the positive control cells, the M9 and M14
isolates and the negative control muscle tissue cells. These
cells were from fast-proliferating cell cultures. Tubulin was
used as the positive control, and all the cultures had a
similar signal (Fig. 6).
Figure 3. Expression of Melan-A, MAGE-1, and MAGE-3 detected
by FACS analysis. Values are a mean of two experiments. The positive
control cells were from passage 32 (P32), while the primary isolates
were from second passage (P2).
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Discussion
We successfully developed and established a protocol for
routine isolation and establishment of primary equine
melanoma cells. Eight primary equine melanoma cell
cultures out of 13 excised melanoma tissues grew in vitro,
which corresponds to a success rate of 62%. The
histological analysis confirmed that all the primary cultures
that grew in vitro were excised from melanocytic tumors.
According to our knowledge, this is the first study with the
highest success rate in establishment and primary equine
melanoma cell cultures.
Although histological examination showed no major
differences between the tumors that grew and those that did
not grow in culture, the hematoxylin and eosin staining used
in our study did not differentiate between viable and necrotic
cells in the melanoma tissues. We presume that the lack of
growth in five melanoma tissue could be attributed to a low
density of viable cells in the melanoma tissue.
All the primary cell cultures that adhered to the plates
after isolation had pigmentation though the levels of
pigmentation different. Variable pigmentation intensities
were also previously reported in cultured primary human
melanocytes (Hanke et al. 2005). The level of pigmentation
was not as intense as in the excised tissue, and this can be
attributed to the fact that melanoma cell cultures may
rapidly alter mRNA and protein expression due to a lack of
cell–cell interactions as previously indicated (Hofbauer et
al. 2001). Loss of melanin granules in melanoma culture
had also been reported previously in canine melanoma
(Wolfe et al. 1987; Ritt et al. 1998; Koenig et al. 2001).
However, it should be also taken into consideration that
Figure 4. Confocal microscopy
detection of the expression of
Melan-A in melanoma cells; (a
and b), positive control—P32;
(c and d), M1-P2; (e and f) M9-
P2. Figures on the left are xy-
projections of chosen slices,
while figures on the right show
the xz- and yz-section projec-
tions with arrows showing the
presence of clear intracellular
staining. Passage numbers are in
italics.
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irregular intensities of pigmentation were also detected in
the histology sections of the excised equine melanoma
tissue. This was consistent with observations made in a
previous study on equine melanoma tissue (Seltenhammer
et al. 2004).
FACS analysis showed that more than 80% of the
positive cell culture had the cells expressing Melan-A.
These cells additionally had very high amounts of Melan-A
detected by confocal microscopy. It is, therefore, not
surprising that it is only in these cells that a positive
Melan-A signal could be detected by western blotting. On
the other hand, the proportion of cells expressing Melan-A
in our isolated cultures, ranged from 20–42%, and the
Melan-A signal in most of the cells was low. These
differences could be attributed to the fact that the positive
control cells have been in culture for extended periods and
had been passaged more than 20 times. A previous study,
too, had shown that canine melanoma cells that expressed
Melan-A, were on passages above 50 (Koenig et al. 2001).
Cells that have undergone several passages could have
undergone in vitro selection resulting in expressing of high
levels of Melan-A, since longer cultivation of melanoma
cells has been shown to influence gene expression (Ritt et
al. 2000). In contrast, the cells isolated in our study, were
analyzed after one or two passages and we assume that at
this point, no in vitro selection had occurred as yet. We
purposely did not want to induce any in vitro selection that
might influence the expression of genes that might be of
interest later on in the study. However, despite this, the
presence of cells expressing Melan-A confirmed that we
had successfully established melanoma cell cultures since
Melan-A is specific for melanoma cells and is not expressed
in other cells or other tumors (van Dinten et al. 2005).
Weak MAGE-1 and MAGE-3 signals could only be
detected using the more sensitive FACS analysis and
confocal microscopy. Using western blotting, MAGE-1
and MAGE-3 antibodies recognized several bands. Previ-
ous studies had also shown that the MAGE-3 antibody
(57B) recognizes other members of the MAGE family,
including MAGE-1, -4, -6, and -12 and, thus, regarded as a
multi-MAGE antibody (Busam et al. 2000). However, none
of the bands detected was strong enough for us to draw any
conclusions on which MAGE proteins were highly
expressed. It should be taken into account that MAGE
Figure 6. Expression of Melan-A and PCNA detected by western
blot analysis. The positive control cells were from the 32nd passage
(P32), while the primary isolates were from third passage (P3).
Tubulin was used as a loading control.
Figure 5. Confocal microscopy
detection of the expression of
MAGE-1 (a and b) and MAGE-
3 (c and d), in melanoma posi-
tive control cells at passage 32
(P32), which is representative of
the expression in the primary
isolates. Figures on the left are
xy-projection of chosen slices
while figures on the right show
the xz- and yz-section projec-
tions with arrows showing the
presence of clear intracellular
staining.
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genes are absent in melanocytic nevi and malignant
melanomas (Busam et al. 2000). Our analyses of histolog-
ical sections and isolated cell cultures could not differen-
tiate between malignant and benign melanoma, however,
most of melanomas of gray horses eventually metastasize
and two cases (M4 and M14) were presumably malignant
with this assumption being strengthened by the presence of
vascular invasion. We can, therefore, not rule out that
malignancy was the cause of decreased or lack of clear
expression of MAGE genes. On the other hand, in a
previous study, MAGE antibodies had detected no signal
with equine melanoma tissue (Heinzerling et al. 2001),
hence, sensitivity of these antibodies to equine MAGE
proteins should be studied.
PCNA is a 36-kDA molecule that plays an essential role
in nucleic acid metabolism as a component of the
replication and repair machinery. It functions as the
accessory protein for DNA polymerase δ, required for
progressive chromosomal DNA synthesis in the S phase
and it interacts with cellular proteins involved in cell-cycle
regulation and checkpoint control (Kelman 1997). With this
being taken into consideration, PCNA is, thus, not an
exclusive marker for melanoma. However, higher expres-
sion of PCNA was previously correlated with aggressive
clinical behavior in various tumors including cutaneous
malignant melanomas in humans (Ben-Izhak et al. 2002). In
our study, the expression of PCNA was higher in cells that
rapidly proliferated in vitro including M14 that had
vascular invasion and most likely malignant. However,
more studies are required to confirm the malignancy and if
there is any correlation between the level of PCNA
expression and clinical behavior of equine melanoma.
Our study is, therefore, a step forward in providing an
appropriate model for preclinical studies for development
of potential treatment for melanomas. Horses spontaneously
develop metastatic melanoma that resembles the human
disease and primary equine melanoma cell cultures would
be highly relevant for preclinical studies testing new
immunotherapy protocols. The in-vitro-cultured equine
melanoma cells would offer preclinical model to test the
efficacy of potential therapies both for equine and human
melanomas. Cultured melanoma cells would provide
reliable and reproducible sources of tissue to develop and
refine potential therapeutic approaches. They would also
allow therapeutic manipulation of genes and proteins in
living cells.
Previous studies had shown that intratumoral injection of
interleukin-18 and interleukin-12 DNAs showed some
inhibitory effect on melanoma growth in gray horses
(Heinzerling et al. 2001; Stähli 2005). However, only a
very low proportion of the tumors resolved completely,
while the others just decreased in size without resolution. It
remains to be determined if the lack of complete resolution
was due to decreased DNA delivery to the melanoma cells
or degradation of DNA before delivery. Having established
primary equine melanoma cells would address this issue
while allowing unlimited studies to be done to determine
delivery of therapeutic gene in melanoma cells. This would
give an insight on the most efficient gene delivery
formulations and methods in these cells.
We were successful in the development and establish-
ment of a protocol for routine isolation and cultivation of
primary equine melanoma cells. The characterization of
MAA is by no means exhaustive since we only used
antibodies that were available in our institute at the point
of isolation. To do a thorough characterization, more
experiments will be required to determine the expression
of other melanoma-associated antigens. Also, the effect of
longer cultivation on gene expression will need to be
determined.
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